Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by IGC Pharma, Inc.

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Announces Results of its 2024 Annual Stockholders Meeting
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Reports First Quarter Fiscal 2025 Results
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Adds Advisor in Artificial Intelligence
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Reports Third Quarter Fiscal 2024 Results
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Reports Second Quarter Fiscal 2024 Results
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Announces Results of its 2023 Annual Stockholders Meeting
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials
From IGC Pharma, Inc.
Via Business Wire
Tickers IGC
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.